Clinical Trial Result Information

Protocol number
ML18496

Title of Study
An open, prospective, randomized, controlled study comparing CellCept® (mycophenolate mofetil, MMF) administered as a component of tacrolimus based immunosuppression therapy, at a loading dose of 3 g daily during the initial post-transplant period versus CellCept® administered at a dose of 2 g daily, in recipients of renal allografts: a multicentre pilot study

Sponsor
Hoffmann-La Roche Ltd

Company division
Pharmaceutical

Product name
CellCept

Generic name
mycophenolate mofetil

Therapeutic area
Kidney Transplantation

Clinical study summary
This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.

Phase of development
III

Date of report
To be Published

Click here for the protocol registry listing of this trial.